These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29984884)

  • 41. Longterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study.
    Myasoedova E; Crowson CS; Green AB; Matteson EL; Gabriel SE
    J Rheumatol; 2014 Aug; 41(8):1638-44. PubMed ID: 24986852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.
    Agarwal A; Wei G; Boucher R; Ahmed F; Beddhu S
    Nephrology (Carlton); 2021 Apr; 26(4):303-311. PubMed ID: 33538091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of blood pressure index on clinical outcomes in patients with heart failure and chronic kidney disease.
    Yuan Y; Liu M; Zhang S; Lin Y; Huang Y; Zhou H; Xu X; Zhuang X; Liao X
    ESC Heart Fail; 2023 Dec; 10(6):3330-3339. PubMed ID: 37667525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2018 Aug; 36(8):1622-1636. PubMed ID: 29847485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis.
    Sakima A; Satonaka H; Nishida N; Yatsu K; Arima H
    Hypertens Res; 2019 Apr; 42(4):483-495. PubMed ID: 30948822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensive Blood Pressure Treatment for Resistant Hypertension.
    Tsujimoto T; Kajio H
    Hypertension; 2019 Feb; 73(2):415-423. PubMed ID: 30580680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).
    Shapiro BP; Ambrosius WT; Blackshear JL; Cushman WC; Whelton PK; Oparil S; Beddhu S; Dwyer JP; Gren LH; Kostis WJ; Lioudis M; Pisoni R; Rosendorff C; Haley WE;
    Hypertension; 2018 Jun; 71(6):1064-1074. PubMed ID: 29712745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines.
    Egan BM; Li J; Wagner CS
    Hypertension; 2016 Aug; 68(2):318-23. PubMed ID: 27354422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
    Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.
    Beddhu S; Shen J; Cheung AK; Kimmel PL; Chertow GM; Wei G; Boucher RE; Chonchol M; Arman F; Campbell RC; Contreras G; Dwyer JP; Freedman BI; Ix JH; Kirchner K; Papademetriou V; Pisoni R; Rocco MV; Whelton PK; Greene T
    J Am Soc Nephrol; 2019 Aug; 30(8):1523-1533. PubMed ID: 31324734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database.
    Gong Y; Smith SM; Handberg EM; Pepine CJ; Cooper-DeHoff RM
    J Clin Hypertens (Greenwich); 2018 Apr; 20(4):620-624. PubMed ID: 29532983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
    Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
    J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular Risk in Patients With Treated Isolated Diastolic Hypertension and Isolated Low Diastolic Blood Pressure.
    Chang WL; Chen YF; Lee YH; Shiu MN; Chang PY; Guo CY; Huang CJ; Chiang CE; Chen CH; Chuang SY; Cheng HM
    J Am Heart Assoc; 2024 Apr; 13(8):e032771. PubMed ID: 38606761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study.
    Lin Z; Xiao Z; Chen W; Xu W; Huang C; Xie J; Jin M; Wei X; He S; Xie Z; Liao W; Liao Y; Feng W; Chen Y; Bin J
    Eur J Prev Cardiol; 2023 Aug; 30(10):969-977. PubMed ID: 36947144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time-weighted blood pressure with cardiovascular risk among patients with or without diabetes.
    Jiang Z; Shao F; Hu J; Zhuang Q; Cooray PLRK; Chen K; Wu Z; Chen T; Li C
    Clin Cardiol; 2024 Jan; 47(1):e24213. PubMed ID: 38269631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.